1. Home
  2. NCMI vs ELDN Comparison

NCMI vs ELDN Comparison

Compare NCMI & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

N/A

Current Price

$1.59

Market Cap

207.0M

ML Signal

N/A

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

N/A

Current Price

$2.61

Market Cap

219.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCMI
ELDN
Founded
2005
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.0M
219.4M
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
NCMI
ELDN
Price
$1.59
$2.61
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$4.44
★ $9.00
AVG Volume (30 Days)
621.4K
★ 887.3K
Earning Date
11-10-2026
11-17-2026
Dividend Yield
★ 5.56%
N/A
EPS Growth
★ 52.17
30.67
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.27
N/A
Revenue Next Year
$2.48
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.43
$1.35
52 Week High
$4.34
$4.49

Technical Indicators

Market Signals
Indicator
NCMI
ELDN
Relative Strength Index (RSI) 28.85 52.52
Support Level N/A $2.63
Resistance Level $2.30 $3.19
Average True Range (ATR) 0.10 0.23
MACD -0.01 0.04
Stochastic Oscillator 26.47 45.89

Price Performance

Historical Comparison
NCMI
ELDN

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Share on Social Networks: